MRVI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

09.03.25 21:00 Uhr

Werte in diesem Artikel

NEW YORK, March 9, 2025 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. ("Maravai" or "the Company") (NASDAQ: MRVI) and certain of its officers.

Bronstein, Gewirtz & Grossman, LLC (PRNewsfoto/Bronstein, Gewirtz & Grossman, LLC)

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Maravai securities between August 7, 2024 and February 24, 2025, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/MRVI.

Case Details

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants failed to disclose to investors that: (1) Maravai lacked adequate internal controls over financial reporting related to revenue recognition; (2) as a result, the Company inaccurately recognized revenue on certain transactions during fiscal 2024; (3) its goodwill was overstated; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/MRVI. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Maravai you have until May 5, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mrvi-investor-alert-bronstein-gewirtz--grossman-llc-announces-that-maravai-lifesciences-holdings-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-302393698.html

SOURCE Bronstein, Gewirtz & Grossman, LLC

Ausgewählte Hebelprodukte auf Maravai LifeSciences A

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Maravai LifeSciences A

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Maravai LifeSciences Holdings Inc Registered -A-

Wer­bung